"Cytochrome P-450 CYP2C19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.
| Descriptor ID |
D065731
|
| MeSH Number(s) |
D08.244.453.491.500.700 D08.811.682.690.708.170.450.500.700 D12.776.422.220.453.491.500.700
|
| Concept/Terms |
Cytochrome P-450 CYP2C19- Cytochrome P-450 CYP2C19
- CYP2C19, Cytochrome P-450
- Cytochrome P 450 CYP2C19
- P-450 CYP2C19, Cytochrome
- CYPIIC19
- S-Mephenytoin 4'-Hydroxylase
- 4'-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4' Hydroxylase
- CYP2C19
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C19".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C19".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C19" by people in this website by year, and whether "Cytochrome P-450 CYP2C19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 5 | 8 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C19" by people in Profiles.
-
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. Clin Transl Sci. 2021 01; 14(1):153-162.
-
Advances in the Pharmacogenomics of Antiplatelet Therapy. Am J Ther. 2020 Sep/Oct; 27(5):e477-e484.
-
Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):181-186.
-
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2019 06 01; 93(7):1246-1252.
-
An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. Bioanalysis. 2018 Oct 01; 10(19):1577-1590.
-
Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis? Antimicrob Agents Chemother. 2018 09; 62(9).
-
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. Thromb Haemost. 2018 Sep; 118(9):1656-1667.
-
Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol. 2018 08; 28(8):945-954.
-
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Sci Rep. 2018 01 19; 8(1):1229.
-
Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. Drug Metab Pers Ther. 2017 12 20; 32(4):183-190.